Ihuman Inc Stock Performance
| IH Stock | USD 2.35 0.01 0.43% |
On a scale of 0 to 100, Ihuman holds a performance score of 4. The company retains a Market Volatility (i.e., Beta) of 0.38, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Ihuman's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ihuman is expected to be smaller as well. Please check Ihuman's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Ihuman's current trending patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ihuman Inc are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak technical indicators, Ihuman demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.43 | Five Day Return (0.84) | Year To Date Return 38.24 | Ten Year Return (85.31) | All Time Return (85.31) |
1 | Do Its Financials Have Any Role To Play In Driving iHuman Inc.s Stock Up Recently | 03/27/2025 |
2 | iHuman declares 0.10 dividend | 03/28/2025 |
3 | Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia | 04/01/2025 |
4 | Investors Dont See Light At End Of iHuman Inc.s Tunnel And Push Stock Down 38 | 04/14/2025 |
5 | iHuman Releases Complete 2024 Financial Results in Annual SEC Filing - Stock Titan | 04/28/2025 |
6 | UPDATE - International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 | 05/08/2025 |
7 | International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 | 05/13/2025 |
| Ihuman dividend paid on 15th of May 2025 | 05/15/2025 |
8 | iHuman Might Have The Makings Of A Multi-Bagger | 05/27/2025 |
9 | iHuman Inc. Sees Significant Increase in Short Interest - MarketBeat | 05/30/2025 |
10 | Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia | 06/05/2025 |
| Begin Period Cash Flow | 1.2 B |
Ihuman Relative Risk vs. Return Landscape
If you would invest 215.00 in Ihuman Inc on March 10, 2025 and sell it today you would earn a total of 20.00 from holding Ihuman Inc or generate 9.3% return on investment over 90 days. Ihuman Inc is generating 0.2906% of daily returns and assumes 5.5274% volatility on return distribution over the 90 days horizon. Put differently, 49% of stocks are less risky than Ihuman on the basis of their historical return distribution, and some 95% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
Ihuman Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ihuman's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ihuman Inc, and traders can use it to determine the average amount a Ihuman's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0526
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.53 actual daily | 49 51% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Ihuman is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ihuman by adding it to a well-diversified portfolio.
Ihuman Fundamentals Growth
Ihuman Stock prices reflect investors' perceptions of the future prospects and financial health of Ihuman, and Ihuman fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ihuman Stock performance.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0313 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | (39.07 M) | ||||
| Shares Outstanding | 22.72 M | ||||
| Price To Earning | 7.83 X | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 0.13 X | ||||
| Revenue | 922.2 M | ||||
| Gross Profit | 640.15 M | ||||
| EBITDA | 85.57 M | ||||
| Net Income | 98.59 M | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 16.08 X | ||||
| Total Debt | 14.91 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 2.27 X | ||||
| Book Value Per Share | 18.47 X | ||||
| Cash Flow From Operations | 58.55 M | ||||
| Earnings Per Share | 0.25 X | ||||
| Market Capitalization | 121.08 M | ||||
| Total Asset | 1.42 B | ||||
| Retained Earnings | (42.1 M) | ||||
| Working Capital | 888.27 M | ||||
About Ihuman Performance
By evaluating Ihuman's fundamental ratios, stakeholders can gain valuable insights into Ihuman's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ihuman has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ihuman has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 30.38 | 28.86 | |
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.07 | 0.07 | |
| Return On Equity | 0.10 | 0.10 |
Things to note about Ihuman Inc performance evaluation
Checking the ongoing alerts about Ihuman for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ihuman Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ihuman Inc had very high historical volatility over the last 90 days | |
| On 15th of May 2025 Ihuman paid $ 0.1 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia |
- Analyzing Ihuman's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ihuman's stock is overvalued or undervalued compared to its peers.
- Examining Ihuman's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ihuman's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ihuman's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ihuman's stock. These opinions can provide insight into Ihuman's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ihuman Stock analysis
When running Ihuman's price analysis, check to measure Ihuman's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ihuman is operating at the current time. Most of Ihuman's value examination focuses on studying past and present price action to predict the probability of Ihuman's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ihuman's price. Additionally, you may evaluate how the addition of Ihuman to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |